Clinical Trials · NCT07424430

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Phase
N/A
Recruitment status
Completed
Sponsor
LMC Diabetes & Endocrinology Ltd.
Enrollment
3,392
Start date
Feb 2026
Locations
1 site, Canada
Primary endpoint
Change in HbA1c- 3 Years
View Semaglutide compound reference